首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   145篇
  免费   14篇
  国内免费   13篇
基础医学   4篇
临床医学   16篇
内科学   65篇
神经病学   3篇
特种医学   4篇
外科学   8篇
综合类   50篇
预防医学   1篇
药学   11篇
中国医学   10篇
  2024年   1篇
  2023年   3篇
  2022年   3篇
  2021年   11篇
  2020年   3篇
  2019年   6篇
  2018年   4篇
  2017年   7篇
  2016年   3篇
  2015年   4篇
  2014年   18篇
  2013年   8篇
  2012年   15篇
  2011年   13篇
  2010年   13篇
  2009年   13篇
  2008年   2篇
  2007年   5篇
  2006年   12篇
  2005年   9篇
  2004年   5篇
  2002年   1篇
  2001年   1篇
  1999年   2篇
  1996年   1篇
  1992年   1篇
  1991年   1篇
  1990年   1篇
  1985年   1篇
  1984年   1篇
  1982年   1篇
  1978年   2篇
  1974年   1篇
排序方式: 共有172条查询结果,搜索用时 15 毫秒
1.
Coronary no-reflow phenomenon is a lethal mechanism of ongoing myocardial injury, following successful revascularization of an infarct-related coronary artery. Incidence of this phenomenon is high following percutaneous intervention, and is associated with adverse in-hospital and long-term outcomes. Several mechanisms such as ischemia-reperfusion injury and distal microthromboembolism in genetically susceptible patients and those with preexisting endothelial dysfunction have been implicated. However, the exact mechanism in humans is still poorly understood. Several investigative and treatment strategies within and outside the cardiac catheterization laboratory have been proposed, but have not uniformly shown success in reducing mortality or in preventing adverse left ventricular remodeling resulting from this condition. The aim of this article is to provide a brief and concise review of the current understanding of the pathophysiology, clinical predictors, and investigations and management of coronary no-reflow phenomenon.  相似文献   
2.
目的]探讨D-二聚体/纤维蛋白原比值(DFR)对老年急性ST段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入治疗(PCI)术中慢血流/无复流(SF/NRF)的预测价值。[方法]回顾性分析240例接受急诊PCI的老年STEMI患者,依据术后冠状动脉远端血流情况分为SF/NRF组(42例)和非SF/NRF组(198例),比较两组患者基线资料、介入相关指标、DFR等,分析SF/NRF的影响因素及DFR对SF/NRF的预测价值。[结果]SF/NRF组心功能Killip 2~3级、肌酸激酶同工酶峰值、心肌肌钙蛋白I峰值、D-二聚体、纤维蛋白原和DFR均显著高于非SF/NRF组(P<0.05)。SF/NRF组症状发作到首份心电图时间显著长于非SF/NRF组,术前TIMI血流0级比例显著高于非SF/NRF组(P<0.05),而有创收缩压、有创舒张压显著低于非SF/NRF组(P<0.05)。多因素回归分析显示症状发作到首份心电图时间和DFR是SF/NRF的独立预测因素。ROC曲线分析显示,当DFR>0.28时,DFR对SF/NRF的预测价值较高,曲线下面积为0.818(95%CI 0.763~0.864,P<0.01),灵敏度为73.81%,特异度为75.76%。[结论]DFR对老年STEMI患者PCI术中SF/NRF的发生具有较高的预测价值。  相似文献   
3.
We assessed the prognostic value of the platelet to lymphocyte ratio (PLR) in primary percutaneous coronary intervention (pPCI). Patients (n?=?440) with acute myocardial infarction (AMI) who underwent pPCI were divided into 2 groups: low PLR (<137) and high PLR (>137). “Thrombolysis In Myocardial Infarction” (TIMI) flow grades and Syntax scores (SXS) were calculated from initial angiograms. In-hospital mortality rate and cardiac adverse events were obtained from medical records. Patients with high PLR had more no-reflow, higher SXS and higher mortality rate (p?<?0.001, p?<?0.001 and p?=?0.008, respectively). In receiver operating characteristic curve analysis, high PLR predicted development of no-reflow (specificity 71% and sensitivity 85%), SXS>22 (specificity 52% and sensitivity 61%) and adverse events (specificity 67% and sensitivity 63%). In multivariate regression analysis, PLR was an independent risk factor for no-reflow, SXS>22 and in-hospital adverse events. In addition to PLR, we present the relationship between mean platelet volume, red cell distribution width and neutrophil to lymphocyte ratio and no-reflow, SXS and in-hospital adverse events.  相似文献   
4.
Introduction: Nicorandil may exert cardioprotective effects in ischemic heart disease. However, its efficacy in combination with early reperfusion is uncertain. The authors performed a meta-analysis of the short- and long-term clinical outcomes of nicorandil administration at the time of primary percutaneous coronary intervention (PCI) in patients with ST-elevated myocardial infarction (STEMI).

Methods: PubMed, MEDLINE, Embase, and the Cochrane Library databases were systematically searched for eligible randomized controlled studies. The primary endpoint was major adverse cardiovascular events (MACE), both in-hospital and post-discharge. The secondary endpoint was the incidence of no-reflow phenomenon.

Results: Ten studies were included (n = 1105). Mean patient age was 63.0 ± 10.0 years; 76.6% of patients were male. Compared with controls who received primary PCI, combined nicorandil/primary PCI significantly reduced in-hospital MACE (pooled odds ratio [OR] 0.16; 95% confidence interval [CI] 0.09–0.27), follow-up MACE (pooled OR 0.53; 95% CI 0.37–0.75), and total MACE (pooled OR 0.27; 95% CI 0.15–0.49). The combined treatment also reduced the incidence of no-reflow phenomenon (pooled OR 0.34; 95% CI 0.23–0.50).

Conclusion: Nicorandil administration at the time of primary PCI is associated with reduced MACE (both short- and long-term) and no-reflow phenomenon in patients with STEMI.  相似文献   

5.
ST-segment elevation myocardial infarction (STEMI) patients with multivessel disease (MVD) have a higher incidence of slow-flow/no-reflow (SF-NR) phenomenon during primary percutaneous coronary intervention (PPCI) than those with single vessel disease. Currently, no effective tools exist to predict the risk of SF-NR in this population. The present study aimed to evaluate whether CHA2DS2-VASc score can be used as a simple tool to predict this risk.This study consecutively included STEMI patients hospitalized in Beijing Anzhen Hospital from January 2005 to January 2015. Among these patients, 1032 patients with MVD were finally enrolled. Patients were divided into SF-NR (+) group and SF-NR (–) group according to whether SF-NR occurred during PPCI. SF-NR was defined as the thrombolysis in myocardial infarction (TIMI) grade ≤2.There were 134 patients (13%) in the SF-NR (+) group. Compared with the SF-NR (–) group, patients in the SF-NR (+) group are elder, with lower left ventricular ejection fraction and higher CHA2DS2-VASc score. Multiple logistic regression analysis indicated that CHA2DS2-VASc score ≥3 (odds ratio [OR], 2.148; 95% confidence interval [CI], 1.389–3.320; P = .001), current smoking (OR, 1.814; 95% CI, 1.19–2.764; P = .006), atrial fibrillation (OR, 2.892; 95% CI, 1.138–7.350; P = .03), complete revascularization (OR, 2.307; 95% CI, 1.202–4.429; P = .01), and total length of stents ≥40 mm (OR, 1.482; 95% CI, 1.011–2.172; P = .04) were independent risk factors of SF-NR. The incidence of SF-NR in patients with CHA2DS2-VASc score ≥3 was 1.7 times higher than that in patients with CHA2DS2-VASc score <3. Additionally, patients with CHA2DS2-VASc score ≥3 plus ≥2 risk factors have 3 times higher incidence of SF-NR than those with CHA2DS2-VASc score ≥3 plus 0 to 1 risk factor.CHA2DS2-VASc score ≥3 can be used as a simple and sensitive indicator to predict SF-NR phenomenon and guide the PPCI strategy in STEMI patients with MVD.  相似文献   
6.
7.
目的 探讨早期应用替罗非班对ST段抬高性心肌梗死(ST segment elevation myocardial infarction,STEMI)患者急诊经皮冠状动脉介入(percutaneous coronary intervention,PCI)治疗疗效的影响.方法 自2009年1月至2012年1月,将186例接受急诊PCI治疗的STEMI患者分为2组:A组为实验组,为早期应用替罗非班的患者共95例,均于PCI治疗前使用;B组为对照组,常规治疗组,未使用替罗非班的患者共91例.分析两组PCI治疗前、后的临床状况、造影血流情况[心肌梗死溶栓(thrombolysis in myocardial infarction,TIMI)血流分级、TIMI心肌灌注分级(TIMI myocardial perfusion,TMP)]及出血事件.记录住院期间及随访6个月内的主要心血管事件的发生率.结果 所有患者均成功行急诊PCI治疗.两组间的基础临床情况及术前造影情况比较,差异无统计学意义(P>0.05).与B组比较,A组PCI治疗后TIMIⅢ级血流的比例(96.5% vs.81.2%,P<0.05)、TMPⅡ级以上血流的比例(96.8% vs.84.2%,P<0.05)均明显增高,发生无复流现象的比例(5.6% vs.13.2%,P<0.05)则明显减少,差异均有统计学意义.两组住院期间主要心血管事件、出血事件的发生率比较,差异无统计学意义(P>0.05).而在随访的6个月期间内,A组主要心血管事件较B组明显减少,差异有统计学意义(P<0.01).结论 在STEMI急诊PCI治疗患者中,早期应用替罗非班能有效预防无复流现象的发生,改善靶血管前向血流,挽救更多存活心肌及改善预后.  相似文献   
8.
冠状动脉微循环功能障碍(CMD)是心脏X综合征、经皮冠状动脉介入治疗(PCI)后无复流等微循环病变的共同发病机制。随着现代影像学的迅速发展,CMD的发生和防治得到越来越多的关注。CMD动物模型是研究疾病发病机制及评价药物作用的必不可少的工具,选择合适的CMD动物模型建立方法是开展CMD实验研究首先面临的问题。临床及实验研究显示,中医药在CMD的防治方面具有一定的特色。如何进一步阐明中药作用机制寻求最佳的中西医结合治疗方案,将是中医药干预CMD的研究重点。该文将从冠状动脉微循环障碍动物模型的建立评价方法及中医药防治冠状动脉微血管环障碍的研究进展进行综述,旨为冠状动脉微循环障碍实验及中医药的实验研究提供参考。  相似文献   
9.
Ultrasound (US) mediated microbubble (MB) destruction facilitates thrombolysis of the epicardial coronary artery in acute myocardial infarction (AMI) but its effect on microvascular thromboemboli remains largely unexplored. We sought to define the acoustic requirements for effective microvascular sonothrombolysis. To model microembolization, microthrombi were injected and entrapped in a 40 μm pore mesh, increasing upstream pressure, which was measured as an index of thrombus burden. MBs (2.0 × 106 MBs/mL) were then infused while pulsed US (1 MHz) was delivered to induce MB destruction immediately adjacent to the thrombus. Upstream pressure decreased progressively during US delivery, indicating a reduction in thrombus burden. More rapid and complete lysis occurred with increasing peak negative acoustic pressure (1.5 MPa > 0.6 MPa) and increasing pulse length (5000 cycles > 100 cycles). Additionally, similar lytic efficacy was achieved at 1.5 MPa without tPA as was at 1.0 MPa with tPA. This model uniquely provides a means to systematically evaluate multiple acoustic and microbubble parameters for the optimization of microvascular sonothrombolysis. This treatment approach for thrombotic microvascular obstruction may obviate the need for adjunctive rt-PA and could have important clinical cost and safety benefits.  相似文献   
10.
目的观察老年人急诊PCI术中冠状动脉内注射替罗非班对术后无复流的影响。方法选择急性心肌梗死行急诊PCI患者163例,随机分为替罗非班组(83例)和对照组(80例)。替罗非班组在导丝通过病变后经导管冠状动脉内注射替罗非班10μg/kg,之后予替罗非班0.15μg/(kg·min)持续静脉滴注24 h。对照组给予常规治疗。观察2组患者TIMI、心肌灌注分级(TMPG),入院后30 d LVEF和左心室舒张末内径,心血管事件及出血并发症。结果替罗非班组TIMI血流3级和TMPG 2~3级比例较对照组明显升高,TIMI血流0~2级和TMPG 0~1级比例较对照组明显降低,差异有统计学意义(P<0.05)。替罗非班组LVEF较对照组明显改善,主要心血管事件较对照组明显降低,差异有统计学意义(P<0.05)。结论急诊PCI术中冠状动脉内注射替罗非班减少无复流,改善心肌灌注和心功能,且不增加心血管事件和并发症。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号